Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | PIKFYVE | Q9Y2I7 | 2/20 | 0.39 |
| ▸ | MAP2 | P11137 | 1/20 | 0.37 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.37 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.36 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 5/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6488914 | 1.00 | F2 (0.41) | F2PIKFYVEMAP2BAZ2BCDK5 | |
| SCHEMBL6488300 | 0.86 | PTGES (0.43) | F2BAZ2BMAPTLMNAALDH1A1 | |
| SCHEMBL6488195 | 0.86 | MAP3K14 (0.46) | F2MAP2BAZ2BMAPTALDH1A1 | |
| SCHEMBL6488296 | 0.86 | PTGES (0.43) | F2BAZ2BMAPTLMNAALDH1A1 | |
| SCHEMBL6495460 | 0.86 | MAPT (0.51) | F2BAZ2BMAPTLMNAALDH1A1 | |
| SCHEMBL6495462 | 0.86 | MAPT (0.51) | F2BAZ2BMAPTLMNAALDH1A1 | |
| SCHEMBL6488194 | 0.86 | MAP3K14 (0.46) | F2MAP2BAZ2BMAPTALDH1A1 | |
| SCHEMBL6502689 | 0.83 | KDM4E (0.43) | F2MAPTLMNAALDH1A1MEN1 | |
| SCHEMBL6502691 | 0.83 | KDM4E (0.43) | F2MAPTLMNAALDH1A1MEN1 | |
| SCHEMBL6500147 | 0.82 | MAP2 (0.36) | F2MAP2BAZ2BCDK5CDK5R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6951881-B2 | (1-substituted-indol-3-yl) alkylidenehydrazinecarboximidamide derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2005-10-04 | — | — | US | claimed |
| US-20030232843-A1 | (1-Substituted-indol-3-yl) alkylidenehydrazinecarboximidamide derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2003-12-18 | — | — | US | claimed |
| US-6951881-B2 | (1-substituted-indol-3-yl) alkylidenehydrazinecarboximidamide derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2005-10-04 | — | — | US | disclosed |
| US-20030232843-A1 | (1-Substituted-indol-3-yl) alkylidenehydrazinecarboximidamide derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232843-A1 | (1-Substituted-indol-3-yl) alkylidenehydrazinecarboximidamide derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR1A | F2 4458/4885PIKFYVE 976/4885MAP2 1097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.